CT1390B is positioned to address a significant unmet need in the treatment of relapsed/refractory acute myeloid leukemia (AML), particularly among patients who are CLL-1 positive. The trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China, indicating a strong local expertise in hematological malignancies. The market for AML therapies is competitive, with several CAR-T therapies in development; however, CT1390B's unique targeting of CLL-1 may provide a differentiated approach. Given the estimated enrollment of 9-18 participants, the trial's results could have implications for future development and partnerships, particularly if safety and efficacy are demonstrated. The trial is not yet recruiting, with an estimated start date in March 2026, which may affect the timeline for potential market entry.